🟢 Spero Therapeutics is trading 6.19% up in pre-market amid broad pre-market strength

Spero Therapeutics is trading at $1.20 (+6.19%) in pre-market amid broad risk-on sentiment.

• No fresh company-specific announcement was identified for September 21, 2026; the latest notable filing was an S-3 effectiveness notice dated September 10.
• The move appears aligned with broad pre-market strength across major U.S. indices and improved global risk appetite, including dovish interpretation of the Bank of Japan decision.
• Recent analyst optimism and an earlier Q2 EPS beat may provide background support, but neither directly explains the overnight move.